139 related articles for article (PubMed ID: 1492223)
1. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
2. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Johnson DH; Greco FA
Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833
[TBL] [Abstract][Full Text] [Related]
3. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Johnson DH; Greco FA
Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
6. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
7. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
Voog E; Merrouche Y; Trillet-Lenoir V; Lasset C; Peaud PY; Rebattu P; Negrier S
Am J Clin Oncol; 2000 Dec; 23(6):614-6. PubMed ID: 11202809
[TBL] [Abstract][Full Text] [Related]
8. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Dial TW; Greco FA
Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Raber MN; Faintuch J; Abbruzzese JL; Sumrall C; Frost P
Ann Oncol; 1991 Jul; 2(7):519-20. PubMed ID: 1911461
[TBL] [Abstract][Full Text] [Related]
11. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
12. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma of unknown primary: identification of a treatable subset?
van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G
Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613
[TBL] [Abstract][Full Text] [Related]
14. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Saghatchian M; Fizazi K; Borel C; Ducreux M; Ruffié P; Le Chevalier T; Théodore C
Ann Oncol; 2001 Apr; 12(4):535-40. PubMed ID: 11398889
[TBL] [Abstract][Full Text] [Related]
15. Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
de Campos ES; Menasce LP; Radford J; Harris M; Thatcher N
Cancer; 1994 Jan; 73(2):470-5. PubMed ID: 8293415
[TBL] [Abstract][Full Text] [Related]
16. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
Briasoulis E; Tsavaris N; Fountzilas G; Athanasiadis A; Kosmidis P; Bafaloukos D; Skarlos D; Samantas E; Pavlidis N
Oncology; 1998; 55(5):426-30. PubMed ID: 9732220
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
19. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.
Osoba D; Band PR; Connors JM; Goldie JH; Knowling MA; Fetherstonhaugh EM
Semin Oncol; 1992 Apr; 19(2 Suppl 5):25-9; discussion 30-1. PubMed ID: 1384140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
